endpts.com·Apr 28, 2026
The FDA has accused ChemoCentryx of manipulating clinical trial results that led to the approval of their drug Tavneos, intensifying efforts to revoke its approval. The agency's claims raise significant concerns about the integrity of the trial data used in the drug's evaluation.
The FDA's accusation of trial manipulation by ChemoCentryx highlights the critical importance of transparent and accurate clinical trial reporting for healthtech and biotech companies. This serves as a reminder to ensure rigorous compliance with regulatory standards to maintain trust and avoid setbacks in drug approval processes.